October 19, 2023
Kezar Life Sciences, Inc., is conducting a clinical trial, PALIZADE (NCT05781750) to evaluate an investigational drug, zetomipzomib (KZR-616), as a potential new treatment for people living with lupus nephritis (LN).
Kezar Life Sciences is currently looking for people with active lupus nephritis (Class III or IV with or without Class V, or Class V alone) to be enrolled into the trial at multiple locations in the United States.
All participants in the trial will either receive zetomipzomib 30 mg or 60 mg, or placebo, given through a once-weekly subcutaneous injection for 52 weeks in addition to the study-specific medication regimen. Participants must be willing to take and then lower steroid doses during the study. A kidney biopsy confirming kidney involvement due to lupus is required, which can be completed during the screening period of the study at no cost to the participant if one has not been completed within one year prior to screening.
Additionally, study drug, all study assessments and procedures will be provided at no cost to participants. Remote home trial and travel concierge services may also be available.
Please contact PALIZADE@kezarbio.com or visit the trial website for additional information.
Zetomipzomib (KZR-616) is an investigational product and has not been approved for commercial use in the United States or any other country for any indication.
Zetomipzomib (KZR-616) is an investigational drug being studied for the treatment of multiple autoimmune diseases including lupus nephritis (LN), a serious manifestation of systemic lupus erythematosus (SLE). The primary target of zetomipzomib is the immunoproteasome, structures that play an important role in regulating the normal function of the immune system. LN is an autoimmune condition that involves inflammation of the kidneys and occurs when the immune system attacks the kidneys. The current approach for treating LN focuses on suppressing the immune system with steroids, which comes with side effects such as an increased risk of infection. Zetomipzomib, however, has the potential to balance an overactive immune system without direct immune suppression and is being studied as a potential steroid-sparing therapy for people living with LN.
